Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 9Terminated 2Unknown 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 9Other solid neoplasm 3Gastrointestinal 3Thoracic 2Sarcoma 2Gynecologic 2Genitourinary 2Head & Neck 1

Conditions

Uterine Cervical Neoplasms 1Endometrial Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × ixabepilone × Gynecologic × Clear all
NCT00924066 2019-11-21

Ixabepilone to Treat Cervical Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
41 enrolled 11 charts
Gynecologic

Uterine Cervical Neoplasms

NCT00883116 2017-03-09

IXAMPLE2

R-Pharm

Phase 3 Terminated
551 enrolled 13 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡